Efficacy of Gemcitabine-based Chemotherapy in Clear Cell Sarcoma of Soft Tissue.
Clear cell sarcoma
EWSR1 translocation
chemotherapy
gemcitabine
Journal
Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
18
10
2020
revised:
07
11
2020
accepted:
08
11
2020
entrez:
8
12
2020
pubmed:
9
12
2020
medline:
18
12
2020
Statut:
ppublish
Résumé
Clear cell sarcoma (CCS) is an aggressive sarcoma subtype, resistant to conventional anthracycline-based chemotherapy and radiation. The diagnosis is often challenging due to similarities with malignant melanoma. We aimed to analyse the activity of gemcitabine-based chemotherapy in a cohort of patients with CCS treated at the Royal Marsden Hospital. Five patients with metastatic CCS received gemcitabine as first- or second-line systemic therapy. The median time-to-progression was 10 weeks. The median number of cycles of gemcitabine-based therapy was 3 (range=2-7 cycles). Median overall survival in our cohort was 66 months from the initial diagnosis but in the metastatic setting, the overall survival was reduced to 28 months. Gemcitabine-based therapy has modest activity in CCS. There remains a significant unmet medical need for novel, effective therapies for this disease.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
Clear cell sarcoma (CCS) is an aggressive sarcoma subtype, resistant to conventional anthracycline-based chemotherapy and radiation. The diagnosis is often challenging due to similarities with malignant melanoma.
PATIENTS AND METHODS
METHODS
We aimed to analyse the activity of gemcitabine-based chemotherapy in a cohort of patients with CCS treated at the Royal Marsden Hospital.
RESULTS
RESULTS
Five patients with metastatic CCS received gemcitabine as first- or second-line systemic therapy. The median time-to-progression was 10 weeks. The median number of cycles of gemcitabine-based therapy was 3 (range=2-7 cycles). Median overall survival in our cohort was 66 months from the initial diagnosis but in the metastatic setting, the overall survival was reduced to 28 months.
CONCLUSION
CONCLUSIONS
Gemcitabine-based therapy has modest activity in CCS. There remains a significant unmet medical need for novel, effective therapies for this disease.
Identifiants
pubmed: 33288595
pii: 40/12/7003
doi: 10.21873/anticanres.14725
doi:
Substances chimiques
Antimetabolites, Antineoplastic
0
Deoxycytidine
0W860991D6
Gemcitabine
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7003-7007Informations de copyright
Copyright © 2020 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.